The Utility of feNO in the Differential Diagnosis of Chronic Cough: The Response to Anti-inflammatory Therapy With Prednisolone and Montelukast (TUF)

NCT02479074 Phase 4 COMPLETED

In this study the investigators wish to explore the difference in 24 hr. cough counts measured using the Hull Automated Cough Counter (HACC), from baseline and after two weeks treatment with either montelukast or prednisolone in patients with an NO measurement of ≥30 ppb at screening.

Details

Lead sponsor	Hull University Teaching Hospitals NHS Trust
Phase	Phase 4
Status	COMPLETED
Enrolment	49
Start date	2016-01
Completion	2017-03-09

Conditions

• Cough

Interventions

• Montelukast (High FeNO group)
• Prednisolon, Montelukast (High FeNO)
• Montelukast (Low FeNO group)

Primary outcomes

• Hull Automated Cough counter — 28 days
  To determine the difference in objective measure of cough as demonstrated by 24 hr cough counts at the baseline, after 2 and 4 weeks treatment between three treatment groups with an associated elevated FeNO.

Countries

United Kingdom